Nehad Soloman, MD, FACR

Using the ESSDAI as a review-of-systems guide and tracking immunologic markers can help rheumatologists prepare for targeted Sjögren’s therapies.

FcRn blockade, CD40 ligand inhibition, dual BAFF and APRIL blockade, and repurposed DMARDs are expanding treatment options in Sjögren’s disease.

Payer reliance on the ESSDAI and widespread underdiagnosis may limit access to new Sjögren’s disease therapies without better screening in practice.

Ianalumab may best suit Sjögren’s patients with systemic, B-cell-driven disease, and phase 3 safety data have so far tracked closely with placebo.

Ianalumab met its primary end point in 2 phase 3 Sjögren’s disease trials, though the modest effect size shapes which patients may benefit most.

Disease heterogeneity, irreversible glandular damage, and imperfect outcome measures help explain why Sjögren’s disease trials repeatedly fell short.

Nehad Soloman, MD, FACR; Andrew Sharobeem, DO, FACR, and Sunil Patel, MD, explore the nephrologist's vital role in gout diagnosis, treatment options for gout patients with chronic kidney disease, and strategies for managing refractory gout and its associated challenges.

Nehad Soloman, MD, FACR; Andrew Sharobeem, DO, FACR, and Sunil Patel, MD, explore the nephrologist's vital role in gout diagnosis, treatment options for gout patients with chronic kidney disease, and strategies for managing refractory gout and its associated challenges.

In this discussion, experts focus on emerging treatment options for gout and share tips for monitoring and managing gout in patients with comorbid conditions.

In this discussion, experts focus on emerging treatment options for gout and share tips for monitoring and managing gout in patients with comorbid conditions.

Expert rheumatologists discuss current treatment options for lupus nephritis and emerging therapies with newer mechanisms of action.

Expert rheumatologists discuss current treatment options for lupus nephritis and emerging therapies with newer mechanisms of action.

Expert rheumatologists discuss precision medicine in rheumatoid arthritis. In particular, they discuss available data and the value of various tools in guiding treatment selection in routine clinical practice.

Expert rheumatologists discuss precision medicine in rheumatoid arthritis. In particular, they discuss available data and the value of various tools in guiding treatment selection in routine clinical practice.

In this MEDcast episode, Drs. Soloman, Sharobeem, and Mease discuss newer mechanisms of actions and emerging therapies in rheumatic diseases and tools that are becoming available to rheumatologists to practice precision medicine.

In this MEDcast episode, Drs. Soloman, Sharobeem, and Mease discuss newer mechanisms of actions and emerging therapies in rheumatic diseases and tools that are becoming available to rheumatologists to practice precision medicine.

In this MEDcast episode, Drs Soloman, Sharobeem, Boone and Feldman discuss the use of step therapy in rheumatoid arthritis, how step therapy was intended to be used, how it is actually used, and challenges and solutions to its use.

In this MEDcast episode, Drs Soloman, Sharobeem, Boone and Feldman discuss the use of step therapy in rheumatoid arthritis, how step therapy was intended to be used, how it is actually used, and challenges and solutions to its use.

Nehad Soloman, MD; Joy Schechtman, DO; and Robert Levin, MD, share final thoughts and takeaways on the treatment of rheumatoid arthritis in the community setting.

Nehad Soloman, MD; Joy Schechtman, DO; and Robert Levin, MD, review the integration of precision medicine into the management of rheumatoid arthritis.

Nehad Soloman, MD; Joy Schechtman, DO; and Robert Levin, MD, discuss barriers to rheumatoid arthritis (RA) treatment selection such as insurance access.

Drs Nehad Soloman, Joy Schechtman, and Robert Levine share their thoughts on how MSRC test results impact the treatment selection for patients with RA.

Experts in rheumatology review the molecular signature response classifier (MSRC) test for use in guiding RA treatment selection.

Nehad Soloman, MD, leads a discussion about precision medicine in the treatment arsenal for RA.

Nehad Soloman, MD, Joy Schechtman, DO, and Robert Levine, MD, discuss American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) recommendations regarding appropriate timing when changing therapies in managing RA.

Nehad Soloman, MD, provides final thoughts on what rheumatologists can look forward to in 2023 for rheumatic disease management.

An expert in rheumatology highlights challenges faced in the rheumatology workforce and how to optimize addressing these issues going forward.

Dr Nehad Solman reviews the role of clinical pathways and alternative payment models in rheumatology as well as anticipated changes for 2023.

Rheumatology specialists review factors in switching a patient with RA to a different treatment, including timing, efficacy assessment, and barriers.

Nehad Soloman, MD, Joy Schechtman, DO, and Robert Levine, MD, examine potential risks in continuing a patient on an ineffective treatment in RA.